These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 19602291)

  • 1. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.
    Swisher EM; Gonzalez RM; Taniguchi T; Garcia RL; Walsh T; Goff BA; Welcsh P
    Mol Cancer; 2009 Jul; 8():48. PubMed ID: 19602291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.
    Pennington KP; Wickramanayake A; Norquist BM; Pennil CC; Garcia RL; Agnew KJ; Taniguchi T; Welcsh P; Swisher EM
    Gynecol Oncol; 2013 Mar; 128(3):493-9. PubMed ID: 23246380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas.
    Moes-Sosnowska J; Rzepecka IK; Chodzynska J; Dansonka-Mieszkowska A; Szafron LM; Balabas A; Lotocka R; Sobiczewski P; Kupryjanczyk J
    Cancer Biol Ther; 2019; 20(6):843-854. PubMed ID: 30822218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Kessous R; Octeau D; Klein K; Tonin PN; Greenwood CMT; Pelmus M; Laskov I; Kogan L; Salvador S; Lau S; Yasmeen A; Gotlieb WH
    Gynecol Oncol; 2018 Mar; 148(3):553-558. PubMed ID: 29395310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.
    Ignatov T; Eggemann H; Costa SD; Roessner A; Kalinski T; Ignatov A
    J Cancer Res Clin Oncol; 2014 Sep; 140(9):1457-63. PubMed ID: 24825122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
    Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
    Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer.
    Carser JE; Quinn JE; Michie CO; O'Brien EJ; McCluggage WG; Maxwell P; Lamers E; Lioe TF; Williams AR; Kennedy RD; Gourley C; Harkin DP
    Gynecol Oncol; 2011 Dec; 123(3):492-8. PubMed ID: 21920589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.
    Norquist B; Wurz KA; Pennil CC; Garcia R; Gross J; Sakai W; Karlan BY; Taniguchi T; Swisher EM
    J Clin Oncol; 2011 Aug; 29(22):3008-15. PubMed ID: 21709188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mismatch repair and treatment resistance in ovarian cancer.
    Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
    BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
    Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
    Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma.
    Ibrahim N; He L; Leong CO; Xing D; Karlan BY; Swisher EM; Rueda BR; Orsulic S; Ellisen LW
    Cancer Res; 2010 Sep; 70(18):7155-65. PubMed ID: 20807817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of CHFR and MLH1 methylation in human gastric cancer.
    Li Y; Yang Y; Lu Y; Herman JG; Brock MV; Zhao P; Guo M
    Gastric Cancer; 2015 Apr; 18(2):280-7. PubMed ID: 24748501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
    Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
    Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of gene promoter methylation in prediction of response to platinum-based chemotherapy in epithelial ovarian cancer (EOC).
    Chaudhry P; Srinivasan R; Patel FD
    Cancer Invest; 2009 Oct; 27(8):877-84. PubMed ID: 19548140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
    Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
    Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients.
    Vencken PMLH; Kriege M; Hoogwerf D; Beugelink S; van der Burg MEL; Hooning MJ; Berns EM; Jager A; Collée M; Burger CW; Seynaeve C
    Ann Oncol; 2011 Jun; 22(6):1346-1352. PubMed ID: 21228333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
    Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
    Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.